| ID Source | ID |
|---|---|
| PubMed CID | 313619 |
| CHEMBL ID | 505670 |
| SCHEMBL ID | 22773985 |
| MeSH ID | M0593126 |
| Synonym |
|---|
| nsc228155 |
| nsc-228155 |
| mls000756562 , |
| 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-1-oxidopyridin-1-ium |
| bdbm25469 |
| cid_313619 |
| smr000448993 |
| 7-nitro-4-(1-oxidopyridin-1-ium-2-yl)sulfanyl-2,1,3-benzoxadiazole |
| CHEMBL505670 |
| HMS2796J10 |
| S8312 |
| 113104-25-9 |
| 4-nitro-7-[(1-oxidopyridin-2-yl)sulfanyl]-2,1,3-benzoxadiazole |
| 2-[(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio]pyridine 1-oxide |
| 2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)pyridine 1-oxide , |
| Z1582583180 |
| BS-14426 |
| nsc 228155 |
| CS-0020796 |
| HY-101084 |
| 2-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylthio)pyridine 1-oxide |
| AKOS033457659 |
| CCG-267377 |
| D80527 |
| EX-A3226 |
| SCHEMBL22773985 |
| 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]pyridin-1-ium-1-olate |
| EN300-128886 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 31.6228 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 2.8863 | 0.1409 | 11.1940 | 39.8107 | AID2451; AID2785; AID2787 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 19.9526 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 30.3001 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID504841 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 4.7755 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| luteinizing hormone receptor | Homo sapiens (human) | Potency | 23.9341 | 23.9341 | 30.6323 | 37.9330 | AID602293 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| BRCA1 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| WRN | Homo sapiens (human) | Potency | 15.8489 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 1.2589 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.0132 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 10.4304 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| TSHR protein | Homo sapiens (human) | Potency | 304.8450 | 0.3381 | 19.0466 | 37.9330 | AID602292; AID602441 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 0.2818 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| Smad3 | Homo sapiens (human) | Potency | 1.2589 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 2.2387 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 17.7828 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 0.3981 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 6.9906 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 56.2341 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 35.4813 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722 |
| IDH1 | Homo sapiens (human) | Potency | 0.1458 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.5012 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.9811 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 4.2439 | 0.3548 | 28.0659 | 89.1251 | AID504847; AID602199; AID602200; AID602201; AID602202 |
| fructose-bisphosphate aldolase A | Oryctolagus cuniculus (rabbit) | Potency | 15.8489 | 0.8913 | 16.5762 | 39.8107 | AID2794 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 7.9433 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 22.3872 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| glyceraldehyde-3-phosphate dehydrogenase isoform 1 | Homo sapiens (human) | Potency | 6.3096 | 1.1220 | 11.1877 | 39.8107 | AID2795 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 1.1220 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 19.9526 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 22.3872 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.8184 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 0.9466 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 35.4813 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 84.9214 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 37.2858 | 0.1298 | 10.8331 | 32.6090 | AID493005; AID651600 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 4.4668 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 3.5481 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 2.8184 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 2.8184 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 2.8184 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 1.0000 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 28.1838 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 1.8909 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Vpr | Human immunodeficiency virus 1 | Potency | 10.0000 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 5.6234 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 1.5849 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 35.4813 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 0.8913 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 0.5623 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 35.4813 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 56.2341 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 28.1838 | 0.0757 | 8.4742 | 29.0628 | AID602233 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 7.6349 | 0.0601 | 10.7453 | 37.9330 | AID485367; AID504636; AID504637 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| toll-like receptor 9 | Homo sapiens (human) | IC50 (µMol) | 3.9160 | 1.8690 | 5.4371 | 9.2420 | AID588340 |
| bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 72.6000 | 3.9100 | 83.9944 | 180.9200 | AID1376 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.1000 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | IC50 (µMol) | 66.0000 | 0.0537 | 3.0757 | 10.0000 | AID1440267; AID1440271 |
| Cystathionine gamma-lyase | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.5700 | 2.8609 | 8.0000 | AID1680654 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 (µMol) | 7.6260 | 0.7091 | 5.0549 | 7.7510 | AID588341 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RGS7, partial | Homo sapiens (human) | EC50 (µMol) | 4.7800 | 0.1400 | 2.1300 | 4.7800 | AID1871 |
| WEE1 homolog (S. pombe) | Homo sapiens (human) | EC50 (µMol) | 1.8420 | 1.8420 | 3.8500 | 7.8660 | AID1412 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | EC50 (µMol) | 30.0000 | 0.1350 | 3.3506 | 10.0690 | AID1872 |
| cyclin B1 | Homo sapiens (human) | EC50 (µMol) | 49.7500 | 1.8420 | 1.8420 | 1.8420 | AID1414 |
| regulator of G-protein signaling 19 | Homo sapiens (human) | EC50 (µMol) | 0.8800 | 0.1150 | 3.1756 | 14.1300 | AID1884 |
| regulator of G-protein signaling 16 | Homo sapiens (human) | EC50 (µMol) | 1.3200 | 0.0530 | 3.6258 | 16.0000 | AID1888 |
| recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 12.1600 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
| endoribonuclease toxin MazF | Escherichia coli str. K-12 substr. MG1655 | EC50 (µMol) | 99.0000 | 3.9600 | 9.5157 | 17.4000 | AID588481; AID588502 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 49.7500 | 0.0000 | 1.2626 | 10.0000 | AID1414 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 49.7500 | 0.0000 | 0.7646 | 10.0000 | AID1414 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 49.7500 | 0.0000 | 0.9905 | 10.0000 | AID1414 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 49.7500 | 0.0000 | 1.0528 | 10.0000 | AID1414 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 49.7500 | 0.0000 | 1.1605 | 10.0000 | AID1414 |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | EC50 (µMol) | 1.8420 | 0.0000 | 0.8939 | 7.8660 | AID1412 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Caspase 6, apoptosis-related cysteine peptidase | Homo sapiens (human) | AC50 | 7.2100 | 0.0636 | 11.2358 | 44.9700 | AID720632 |
| WEE1 homolog (S. pombe) | Homo sapiens (human) | CC50 | 6.7590 | 6.7590 | 6.7590 | 6.7590 | AID1413 |
| cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7 | Homo sapiens (human) | AC50 | 12.7100 | 0.0398 | 15.0025 | 50.0000 | AID743267 |
| histone-lysine N-methyltransferase NSD2 isoform 1 | Homo sapiens (human) | AC50 | 5.1200 | 0.2930 | 7.3070 | 19.4400 | AID1053173 |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 3.9110 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
| replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 7.2605 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
| twin arginine protein translocation system - TatA protein | Escherichia coli str. K-12 substr. MG1655 | AC50 | 5.5300 | 0.7070 | 10.9151 | 45.8560 | AID504941 |
| HSP40, subfamily A [Plasmodium falciparum 3D7] | Plasmodium falciparum 3D7 | AbsAC1000_uM | 2.4260 | 0.1290 | 4.1169 | 11.3160 | AID540271 |
| heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 6.8810 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
| hypothetical protein CAALFM_CR05890CA | Candida albicans SC5314 | AC50 | 11.6400 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| H3 histone acetyltransferase | Candida albicans SC5314 | AC50 | 11.6400 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1440270 | Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440267 | Inhibition of recombinant human IDO1 expressed in bacterial expression system using L-Tryptophan as substrate after 25 mins in absence of GSH and presence of tween20 by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID770317 | Selectivity ratio of IC50 for Herpesvirus VP16-CREB (unknown origin)-mediated gene transcription in HEK293T cells to IC50 for CREB (unknown origin)-mediated gene transcription in HEK293T cells | 2013 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19 | Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription. |
| AID1440296 | Cytotoxicity against mouse LLTC cells assessed as reduction in cell viability after 24 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID770320 | Inhibition of CREB-KID/CBP-KIX domain interaction (unknown origin) after 20 hrs by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19 | Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription. |
| AID1680654 | Inhibition of human CSE using L-Cys as the substrate by tandem well based HTS assay | 2019 | Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3 | Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase. |
| AID389950 | Binding affinity to Mycobacterium tuberculosis APS reductase | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Structure-based virtual screening and biological evaluation of Mycobacterium tuberculosis adenosine 5'-phosphosulfate reductase inhibitors. |
| AID770318 | Inhibition of Herpesvirus VP16-CREB (unknown origin)-mediated gene transcription in HEK293T cells by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19 | Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription. |
| AID770319 | Inhibition of CREB (unknown origin)-mediated gene transcription in HEK293T cells preincubated for 30 mins followed by forskolin addition measured after 5 hrs by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19 | Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription. |
| AID1440295 | Inhibition of full length recombinant human His-tagged IDO1 expressed in mouse LLTC cells using L-tryptophan as substrate after 24 hrs | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440272 | Selectivity ratio of IC50 for recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) to IC50 for recombinant human IDO1 expressed in bacterial expression system | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440268 | Inhibition of recombinant human IDO1 expressed in bacterial expression system at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440271 | Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) using L-Tryptophan as substrate after 25 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1798557 | Determination of Dissociation Constant (Kd) from Article 10.1021/jm800571m: \\Structure-based virtual screening and biological evaluation of Mycobacterium tuberculosis adenosine 5'-phosphosulfate reductase inhibitors.\\ | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Structure-based virtual screening and biological evaluation of Mycobacterium tuberculosis adenosine 5'-phosphosulfate reductase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||